ArticleCancer cell international2018
Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis.
Article in Cancer cell international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- CXCL5: A coachman to drive cancer progression.Frontiers in oncology · 2022Pooled it
- Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.Disease markers · 2021Pooled it
- A screening strategy based on machine learning for diagnostic biomarkers in small cell lung cancer.PloS one · 2026Article
- CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.Journal of biomedical science · 2025Article
- Development and validation of a necroptosis-related gene signature for predicting prognosis and immune infiltration in papillary thyroid cancer.Translational cancer research · 2025Article
- Beyond the barrier: the immune-inspired pathways of tumor extravasation.Cell communication and signaling : CCS · 2024Review
- CXCL5 Promotes the Malignant Phenotype of Pancreatic Cancer and Is Associated With Immune Infiltration.Clinical Medicine Insights. Oncology · 2024Article
- Emerging markers of cancer cachexia and their relationship to sarcopenia.Journal of cancer research and clinical oncology · 2023Article
- CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.Scientific reports · 2023Article
- A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.Heliyon · 2023Article
- Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver.Nature communications · 2023Article
- Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer.Scientific data · 2023Article
- TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy.Communications biology · 2023Article
- Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma.Frontiers in cell and developmental biology · 2023Article
- EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer.Oncogene · 2022Article
- CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors.Oncoimmunology · 2022Article
- Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.Frontiers in immunology · 2022Review
- Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.Cancers · 2021Review
- Screening Plasma Exosomal RNAs as Diagnostic Markers for Cervical Cancer: An Analysis of Patients Who Underwent Primary Chemoradiotherapy.Biomolecules · 2021Article
- MicroRNA-432-5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCXCL5 is a member of the CXC-type chemokine family, which has been found to play important roles in tumorigenesis and cancer progression. Recent studies have demonstrated that CXCL5 could serve as a potential prognostic biomarker for cancer patients. However, the prognostic value of CXCL5 is still controversial.
methodsWe systematically searched PubMed, Embase and Web of Science to obtain all relevant articles investigating the prognostic significance of CXCL5 expression in cancer patients. Hazards ratios (HR) with corresponding 95% confidence intervals (CI) were pooled to estimate the association between CXCL5 expression levels with survival of cancer patients.
resultsA total of 15 eligible studies including 19 cohorts and 5070 patients were enrolled in the current meta-analysis. Our results demonstrated that elevated expression level of CXCL5 was significantly associated with poor overall survival (OS) (pooled HR 1.70; 95% CI 1.36-2.12), progression-free survival (pooled HR 1.65; 95% CI 1.09-2.49) and recurrence-free survival (pooled HR 1.49; 95% CI 1.15-1.93) in cancer patients. However, high or low expression of CXCL5 made no difference in predicting the disease-free survival (pooled HR 0.63; 95% CI 0.11-3.49) of cancer patients. Furthermore, we found that high CXCL5 expression was associated with reduced OS in intrahepatic cholangiocarcinoma (HR 1.91; 95% CI 1.31-2.78) and hepatocellular carcinoma (HR 1.87; 95% CI 1.55-2.27). However, there was no significant association between expression level of CXCL5 with the OS in lung cancer (HR 1.25; 95% CI 0.79-1.99) and colorectal cancer (HR 1.16; 95% CI 0.32-4.22, p = 0.826) in current meta-analysis.
conclusionsIn conclusion, our meta-analysis suggested that elevated CXCL5 expression might be an adverse prognostic marker for cancer patients, which could help the clinical decision making process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.